Get a Quote

REMIMAZOLAM BESYLATE
CAS NO.: 1001415-66-2
Chemical Formula: C27H25BrN4O5S
Molecular Weight: 597.5000
DMF&GMP status: Please contact us for more details.
Description:
REMIMAZOLAM is a medication for the induction and maintenance of procedural sedation in adults lasting 30 minutes or less.is a benzodiazepine derivative drug, developed by PAION, in collaboration with Japanese licensee Ono Pharmaceutical as an alternative to the short-acting imidazobenzodiazepine midazolam, for use in induction of anaesthesia and conscious sedation for minor invasive procedures. Remimazolam was found to be both faster acting and shorter lasting than midazolam, and human clinical trials showed a faster recovery time and predictable, consistent pharmacokinetics, suggesting some advantages over existing drugs for these applications.

**The products protected by patents in this product catalog are used for laboratory analysis, research and development, and cannot be sold to any country or region with patent protection and for commercial purpose. If the resulting patent infringement risks and responsibilities will be borne by the buyer.
Approvals
Active Ingredient Dosage Form; Route Strength Proprietary Name Applicant
REMIMAZOLAM BESYLATEPOWDER;INTRAVENOUSEQ 20MG BASE/VIALBYFAVOACACIA PHARMA LTD
Patent Data
Patent No. Patent Expiration Drug Substance Claim Drug Product Claim Patent Use Code
956123604/30/2033U-2968
973754711/07/2031U-2968
977700707/10/2027DP
982725111/07/2031U-2968
991473807/10/2027DP
1005233411/07/2031U-2968
1019521011/07/2031U-2968
1034280011/07/2031U-2968
1047236507/10/2027U-2968
1072252211/07/2031U-2968
Exclusive Data
Exclusivity Code Exclusivity Expiration
NCE 07/02/2025